STAA

STAAR Surgical Company - Q1 2008 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 28, 2008. STAAR Surgical Company develops, manufactures, and sells visual implants and ophthalmic products, primarily intraocular lenses (IOLs) for cataract surgery and the Visian Implantable Collamer Lens (ICL) for refractive surgery. The quarter was defined by the consolidation of STAAR Japan, Inc. (formerly Canon Staar), which became a wholly-owned subsidiary on December 29, 2007, following the acquisition of the remaining 50% interest from Canon Inc.

Key Financial Metrics

Note: Total Debt includes $4,225 in long-term notes payable and $2,098 in capital lease obligations ($905 current + $1,193 long-term).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 20.4% to $17.96 million, driven by the inclusion of STAAR Japan sales ($2.95 million) and favorable currency exchange rates ($1.1 million impact). International sales rose 37%, while U.S. sales declined 11% due to a 15% drop in cataract product sales.
• Acquisition Charges: The company recorded a $3.85 million loss on the settlement of a pre-existing distribution arrangement with Canon Marketing. Additionally, a $1.5 million step-up in inventory value from the acquisition reduced gross margins.
• Expense Increases: Operating expenses rose significantly due to the consolidation of STAAR Japan. General and administrative expenses increased 24%, and marketing and selling expenses increased 22%.
• Balance Sheet: Total assets increased to $62.5 million from $54.2 million, primarily due to the acquisition of intangible assets ($4.2 million) and inventory. The company issued $6.8 million in Series A Redeemable Convertible Preferred Stock as partial consideration for the acquisition.

Guidance, Outlook, and Risks

Management Commentary & Strategy:

• U.S. Market: Management aims to reverse the decline in U.S. cataract sales through new aspheric IOL introductions and to grow U.S. refractive sales (Visian ICL), which saw a 9% increase in Q1 2008.
• Cost Reduction: The company is implementing cost-cutting measures targeting $3.5 million in annualized savings, including workforce reductions in the U.S. and elimination of executive bonuses until profitability trends are positive.
• Liquidity: Management believes current cash balances ($10.5 million) and international cash flow are sufficient to meet funding requirements through the first quarter of 2009, though additional financing may be required if losses persist.

• Regulatory Delays: FDA review of the Toric ICL (TICL) application is on "integrity hold" pending a third-party audit of clinical data. Approval is critical for U.S. refractive growth.
• Legal Proceedings: Two former regional manufacturer representatives (Moody and Parallax) have filed lawsuits claiming interference with contracts, seeking $32 million and $48 million in damages respectively. STAAR believes these claims are without merit but notes litigation outcomes are uncertain.
• Integration Risks: Successful integration of STAAR Japan is critical; risks include employee retention, regulatory approvals in Japan, and maintaining sales levels post-acquisition.
• Economic Sensitivity: Refractive surgery is an elective procedure; an economic downturn could reduce patient demand and sales of the Visian ICL.

Investor Verification Checklist

• Acquisition Accounting: Verify the finalization of the purchase price allocation for STAAR Japan, specifically regarding tax attributes and transaction costs, which are expected to be finalized in Q2 2008.
• U.S. Cataract Trends: Monitor the impact of new aspheric IOL introductions on reversing the 15% decline in U.S. cataract sales.
• FDA Status: Track the progress of the third-party audit regarding the TICL clinical data and the timeline for resubmission to the FDA.
• Litigation Exposure: Review developments in the Moody and Parallax lawsuits to assess potential liability exposure beyond the current "no reserve" stance.
• Cash Burn Rate: Assess whether the $3.5 million cost reduction plan is sufficient to offset operating losses and extend the runway beyond Q1 2009 without dilutive equity raises.